Dec 23, 2015 The Daytrana patch is designed to feed medication in a controlled fashion to the patient through the skin. However, there have been reports of Daytrana skin color loss and other Daytrana side effects associated with the product. While rare, the loss of pigmentation can be permanent. On June 24, 2015, the FDA issued a Drug Safety Communication, warning that use of the Daytrana patch may result in permanent loss of skin colorpigmentation, a condition known as December 21, 2015 Dear Valued Customer: You should have already received a notification from Stericycle Inc.
about a Voluntary Limited RecallMarket Withdrawal of Specific Lots of DAYTRANA (methylphenidate transdermal system).
Attached for your reference Daytrana Voluntary Product Recall Market Withdrawal Jan 15, 2016 The Daytrana patch (methylphenidate transdermal system) is a prescription patch used to treat ADHD.
It belongs to the group of medications called central nervous system stimulants. Daytrana (methylphenidate transdermal system) Daytrana recall dec 2015 republican longlasting symptom control for up to 10 hours when worn for 9 hoursthe recommended maximum wear time. When applied, Daytrana takes effect after 2 hours. Effects will last for up to 3 hours after being removed. Consult your doctor about early removal of the patch. The recall was initiated because some Daytrana patches do not meet the release liner removal specification.
This means that the liner may be more difficult than normal to remove when opening the packaging. When was the recall initiated? The affected lots of Daytrana were recalled by the manufacturer on December 23, 2015. Shire is recalling more of its Daytrana patches for attention deficit hyperactivity disorder, possibly leading to the return of as many as 469, 000 patches.
Shire is recalling more of its Daytrana patches for attention deficit hyperactivity disorder, possibly leading to the return of as many as 469, 000 patches. Shire Undertakes Voluntary Recall of Two Lots of Daytrana Product Noven Pharmaceuticals, Inc.
(NASDAQ: NOVN) today provided an update on the status of Daytrana, the only transdermal patch indicated for the treatment of the symptoms of Attention Deficit Hyperactivity Disorder (ADHD). Recall notice Noven Pharmaceuticals, Inc. Noven Pharmaceuticals, Inc. is recalling the itemslots below due to the amount of effort necessary to remove the adhesive liner from the patch. The first distributor, Dublin, Irelandbased Shire, gave up on the product in 2010, after 10 Daytrana recalls were issued since it was first approved in the United States in 2006.
Dec 07, 2009 This is the eighth recall of the Daytrana patch, a product on which Shire's manufacturer, Noven (NOVN), makes no profit because recall costs far exceed the revenues it UPDATE: In July 2011, FDA began a pilot program to notify people of drug recalls before they are classified in an effort to expedite notifications of human drug product recalls to the public. Aug 11, 2010 Back in December, I suggested that Shire (SHPGY) should ditch Daytrana, its ADHD patch for kids, because the liners on the device malfunctioned so